Latest News

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conf...

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferenc

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississipp...

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, an

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risper...

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class P...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potent

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Prop...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarte...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Pro...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in

Teva and Samsung Bioepis Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculi...

Teva and Samsung Bioepis Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Fina

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class...

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Pote

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Unins...

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured